{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:05:40Z","timestamp":1771553140425,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,28]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We evaluated remission rates and their relationship with baseline characteristics in patients with rheumatoid arthritis treated with the oral Janus kinase inhibitor peficitinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This post hoc analysis of data from two Phase 3 studies (RAJ3 and RAJ4) of peficitinib (100 and 150\u2009mg\/day) in Asian rheumatoid arthritis patients investigated clinical disease activity index (CDAI) remission and low disease activity rates from baseline to Week 52. CDAI, Health Assessment Questionnaire-Disability Index, and van der Heijde\u2013modified total Sharp score remission\/low disease activity rates at Week 52 were evaluated among patients achieving CDAI remission at Weeks 12\/28. Logistic regression analyses explored the relationship between baseline characteristics and CDAI remission\/low disease activity rates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CDAI remission rates increased over time in a dose-dependent manner in both peficitinib-treated groups. Most patients achieving CDAI remission at Weeks 12\/28 also achieved remission at Week 52. Following the multivariate analysis of demographic and baseline characteristics, factors associated with the achievement of CDAI remission\u00a0at Week 28 included male sex, low baseline prednisone dose (RAJ3 only), and low baseline Disease Activity Score 28-C-reactive protein (RAJ4 only).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Peficitinib demonstrated persistent efficacy in clinical remission to Week 52. Baseline characteristics associated with CDAI remission were mostly consistent with previous studies using other disease-modifying antirheumatic drugs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/road059","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T16:57:54Z","timestamp":1686848274000},"page":"453-465","source":"Crossref","is-referenced-by-count":2,"title":["<i>Post hoc<\/i> analysis of\u00a0patients with rheumatoid arthritis under clinical remission in\u00a0two Japanese Phase 3 trials of\u00a0peficitinib treatment (RAJ3 and\u00a0RAJ4)"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan , Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"},{"name":"Saitama Medical University , Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Morita","sequence":"additional","affiliation":[{"name":"Medical Affairs Japan, Astellas Pharma Inc. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-4319","authenticated-orcid":false,"given":"Daisuke","family":"Kato","sequence":"additional","affiliation":[{"name":"Sustainability Department, Astellas Pharma Inc. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Statistical & RWD Science Group, Data Science, Astellas Pharma Global Development Inc. , Northbrook, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Terada","sequence":"additional","affiliation":[{"name":"Statistical & RWD Science Group, Data Science, Development, Astellas Pharma Inc. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"2024032817160377000_R1","first-page":"S237","article-title":"Improved health-related quality of\u00a0life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials","volume":"13","author":"Strand","year":"2007","journal-title":"Am J Manag Care"},{"key":"2024032817160377000_R2","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of\u00a0rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"2024032817160377000_R3","article-title":"Clinical remission of\u00a0rheumatoid arthritis in\u00a0a multicenter real-world study in\u00a0Asia-Pacific region","volume":"15","author":"Sun","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"2024032817160377000_R4","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMra040226","article-title":"Therapeutic strategies for\u00a0rheumatoid arthritis","volume":"350","author":"O\u2019Dell","year":"2004","journal-title":"N Engl J Med"},{"key":"2024032817160377000_R5","doi-asserted-by":"crossref","DOI":"10.1186\/s41232-020-00133-8","article-title":"Rheumatoid arthritis","volume":"40","author":"Tanaka","year":"2020","journal-title":"Inflamm Regen"},{"key":"2024032817160377000_R6","article-title":"Treat-to-target: rheumatoid arthritis in\u00a0adults: diagnosis and\u00a0management: evidence review C","author":"National Guideline Centre (UK)","year":"2018"},{"key":"2024032817160377000_R7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for\u00a0the management of\u00a0rheumatoid arthritis with synthetic and\u00a0biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024032817160377000_R8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.10.003","article-title":"Treatment of\u00a0rheumatoid arthritis: unraveling the conundrum","volume":"65","author":"Zampeli","year":"2015","journal-title":"J Autoimmun"},{"key":"2024032817160377000_R9","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in\u00a0autoimmune diseases","volume":"72","author":"O\u2019Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024032817160377000_R10","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and\u00a0safety of\u00a0the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in\u00a0patients with moderate to severe rheumatoid arthritis in\u00a0Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024032817160377000_R11","article-title":"Drug details: 50 mg Smyraf (peficitinib hydrobromide)","author":"Astellas Pharma Taiwan, Inc"},{"key":"2024032817160377000_R12","article-title":"Smyraf film-coated tablets 100mg","author":"Food and Drug Administration Taiwan"},{"key":"2024032817160377000_R13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in\u00a0rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024032817160377000_R14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2020.1739649","article-title":"Peficitinib for\u00a0the treatment of\u00a0rheumatoid arthritis: an overview from clinical trials","volume":"21","author":"Tanaka","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"2024032817160377000_R15","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and\u00a0safety of peficitinib (ASP015K) in\u00a0patients with rheumatoid arthritis and\u00a0an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024032817160377000_R16","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and\u00a0safety of\u00a0peficitinib (ASP015K) in\u00a0patients with rheumatoid arthritis and\u00a0an inadequate response to methotrexate: results of\u00a0a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in\u00a0Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024032817160377000_R17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40744-021-00280-5","article-title":"Safety and\u00a0effectiveness of\u00a0peficitinib (ASP015K) in\u00a0patients with rheumatoid arthritis: final results (32 months of\u00a0mean peficitinib treatment) from a long-term, open-label extension study in\u00a0Japan, Korea, and\u00a0Taiwan","volume":"8","author":"Takeuchi","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2024032817160377000_R18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for\u00a0the classification of\u00a0rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2024032817160377000_R19","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of\u00a0Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024032817160377000_R20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.berh.2007.02.004","article-title":"The Simplified Disease Activity Index (SDAI) and\u00a0Clinical Disease Activity Index (CDAI) to monitor patients in\u00a0standard clinical care","volume":"21","author":"Aletaha","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2024032817160377000_R21","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2169\/internalmedicine.8723-16","article-title":"Clinical characteristics of\u00a0rheumatoid arthritis patients achieving functional remission after six months of\u00a0non-tumor necrosis factor biological disease-modifying antirheumatic drugs (DMARDs) treatment","volume":"56","author":"Miwa","year":"2017","journal-title":"Intern Med"},{"key":"2024032817160377000_R22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/14397595.2018.1482609","article-title":"Predictive factors for\u00a0structural remission using abatacept: results from the ABROAD study","volume":"29","author":"Murakami","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2024032817160377000_R23","first-page":"467","article-title":"Factors predicting 2 years of\u00a0remission and\u00a0low disease activity in\u00a0rheumatoid arthritis patients treated with TNF-inhibitors","volume":"19","author":"Conigliaro","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"2024032817160377000_R24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/annrheumdis-2021-eular.359","article-title":"Sex differences in\u00a0the efficacy and\u00a0safety of\u00a0tofacitinib in\u00a0rheumatoid arthritis patients: a post hoc analysis of\u00a0phase 3 and\u00a0long-term extension trials","volume":"80","author":"Jones","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024032817160377000_R25","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/acr.20188","article-title":"Predictors for\u00a0remission in\u00a0rheumatoid arthritis patients: a systematic review","volume":"62","author":"Katchamart","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024032817160377000_R26","article-title":"Prevalence and\u00a0predictors for\u00a0sustained remission in\u00a0rheumatoid arthritis","volume":"14","author":"Sung","year":"2019","journal-title":"PLoS One"},{"key":"2024032817160377000_R27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10067-018-4340-7","article-title":"Remission rate and\u00a0predictors of\u00a0remission in\u00a0patients with rheumatoid arthritis under treat-to-target strategy in\u00a0real-world studies: a systematic review and\u00a0meta-analysis","volume":"38","author":"Yu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2024032817160377000_R28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78925-8","article-title":"Predictors for\u00a0clinical effectiveness of\u00a0baricitinib in\u00a0rheumatoid arthritis patients in\u00a0routine clinical practice: data from a Japanese multicenter registry","volume":"10","author":"Takahashi","year":"2020","journal-title":"Sci Rep"},{"key":"2024032817160377000_R29","article-title":"Significance of\u00a0sex in\u00a0achieving sustained remission in\u00a0the Consortium of\u00a0Rheumatology Researchers of\u00a0North America (CORRONA) Cohort of Rheumatoid Arthritis Patients","volume":"64","author":"Jawaheer","year":"2012","journal-title":"Arthritis Care Res Res NIH Public Access"},{"key":"2024032817160377000_R30","first-page":"272","article-title":"Outcomes related to methotrexate dose and\u00a0route of\u00a0administration in\u00a0patients with rheumatoid arthritis: a systematic literature review","volume":"33","author":"Goodman","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2024032817160377000_R31","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000186","article-title":"Efficacy of\u00a0etanercept in\u00a0combination with methotrexate in\u00a0moderate-to-severe rheumatoid arthritis is not dependent on\u00a0methotrexate dosage","volume":"2","author":"Gallo","year":"2016","journal-title":"RMD Open"},{"key":"2024032817160377000_R32","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of\u00a0new JAK inhibitors under development. Just more of\u00a0the same?","volume":"58","author":"Westhovens","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"key":"2024032817160377000_R33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in\u00a0rheumatoid arthritis: an evidence-based review on\u00a0the emerging clinical data","volume":"13","author":"Harrington","year":"2020","journal-title":"J Inflamm Res"},{"key":"2024032817160377000_R34","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","article-title":"Clinical efficacy of\u00a0launched JAK inhibitors in\u00a0rheumatoid arthritis","volume":"58","author":"Taylor","year":"2019","journal-title":"Rheumatology"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/road059\/50734576\/road059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/3\/453\/57109821\/road059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/3\/453\/57109821\/road059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T17:57:13Z","timestamp":1711648633000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/3\/453\/7198599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6,15]]},"published-print":{"date-parts":[[2024,3,28]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/road059","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2023,6,15]]}}}